
From: Rachelle Galant </O=ONETEAM/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=RGALANT>
To: Jinping McCormick
Sent: 3/9/2012 2:47:20 PM
Subject: RE: Actavis 852 / 867 data
Attachments: EAS

Michael and Mike talked about it and they thought a threshold of 50,000 C-2 units (Fentanyl, Methylphenidate, Morphine, Oxy, Oxy/IBu, and Prometh) annually warranted monitoring through Valuetrak.

That would eliminate most of the additional trading partners that we were adding, except for Value.

What are your thoughts?

Rachelle Galant
Senior Product Manager

Actavis
60 Columbia Rd. Bldg B t +1 973-993-4527 @ RGalant@actavis.com <<mailto:RGalant@actavis.com>>
Morristown , NJ 07960 United States w www.actavis.com <<http://www.actavis.com/>>
Internal VoIP number t 125-4527

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Jinping McCormick
Sent: Friday, March 09, 2012 9:06 AM
To: Rachelle Galant
Subject: RE: Actavis 852 / 867 data

Any decisions from the meeting with Michael Clarke?

PLAINTIFFS TRIAL
EXHIBIT
P-23017_00001

Jinping McCormick
Director of Marketing

Actavis

60 Columbia Rd. Bldg B t +1 973-889-6977 @JMCCORMICK@actavis.com
<mailto:JMCCORMICK@actavis.com>

Morristown , NJ 07960 United States f 973-993-4319 w www.actavis.com <<http://www.actavis.com/>>
Internal VoIP number t 1256977

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Conrad Morgiewicz [<mailto:conrad.morgiewicz@valuecentric.com>]
Sent: Friday, March 09, 2012 9:05 AM
To: Jinping McCormick
Cc: Rachelle Galant; Kathi Williams
Subject: RE: Actavis 852 / 867 data

Good Morning Jinping – hope you enjoyed a nice week.

Just a quick follow-up, to see if Actavis has finalized the Trading Partner data requirements.

Let us know if we can help.

Thank you again and have a wonderful weekend

Conrad

978-549-1436

From: Jinping McCormick [<mailto:JMCCORMICK@actavis.com> <<mailto:JMCCORMICK@actavis.com>>]
Sent: Wednesday, March 07, 2012 10:15 AM
To: Conrad Morgiewicz
Cc: Rachelle Galant
Subject: RE: Actavis 852 / 867 data

Conrad,

We will discuss with Mike Dorsey today. He is the sales rep for these accounts which are members of the Premier Purchasing group. We have not kept him in the loop as much as we should have,

Thanks for the update, I will get back to you soon.

Jinping

Jinping McCormick
Director of Marketing

Actavis
60 Columbia Rd. Bldg B **t** +1 973-889-6977 **@** JMCCORMICK@actavis.com
<<mailto:JMCCORMICK@actavis.com>>
Morristown , NJ 07960 United States **f** 973-993-4319 **w** www.actavis.com <<http://www.actavis.com/>>
Internal VoIP number **t** 1256977

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Conrad Morgiewicz [<mailto:conrad.morgiewicz@valuecentric.com>
<<mailto:conrad.morgiewicz@valuecentric.com>>]
Sent: Wednesday, March 07, 2012 10:12 AM
To: Jinping McCormick
Cc: Rachelle Galant
Subject: FW: Actavis 852 / 867 data
Importance: High

Hi Jinping – hope all is well

I understand that you are reviewing the current and proposed trading partners to provide us with the list on Friday but reference email below from Mike Dorsey (Actavis) to Kathi (ValueCentric). Mike has a target live date for the new Trading Partners of March 15th.

How would you like us to proceed? Are you going to speak to Mike?

Thank you

Conrad

978-549-1436

From: Kathi Williams [mailto:kathi.williams@valuecentric.com
<<mailto:kathi.williams@valuecentric.com>>]
Sent: Wednesday, March 07, 2012 9:31 AM
To: Conrad Morgiewicz; Scott Terhaar
Cc: Debbie Shaw; Rianna Ferris
Subject: FW: Actavis 852 / 867 data

Conrad and Scott,

I received the below e-mail from Mike Dorsey at Actavis. Please let me if you have had any feedback from Jinping yet on which TP's we should move forward with. We already have been receiving data for 3 TP's that we can't process because Actavis told us to hold off on those.

Please let me know how you would like me to proceed.

Thanks.

Kathi Williams

Customer Support Analyst

ValueCentric, LLC

Phone: (716) 972-1631

Support Phone: (716) 972-1660

Support E-mail: Support@valuecentric.com <<mailto:Support@valuecentric.com>>

From: Michael Dorsey [mailto:MDORSEY@actavis.com <mailto:MDORSEY@actavis.com>]
Sent: Tuesday, March 06, 2012 8:19 PM
To: Kathi Williams
Cc: Peter Shubiak
Subject: RE: Actavis 852 / 867 data

Kathi,

Would you please give me an update on the progress of 852/867 set-up with Top-Rx, Auburn and Quest Pharmaceuticals? Our Target implementation date is next week – March 15th.

Thank you,

Mike Dorsey
Director, National Accounts

Actavis
60 Columbia Rd. t +1 262-377-0874 @ MDORSEY@actavis.com <mailto:MDORSEY@actavis.com>
Morristown , NJ 07960 United States w www.actavis.com <<http://www.actavis.com/>>
Internal VoIP number

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Kathi Williams [mailto:kathi.williams@valuecentric.com <mailto:kathi.williams@valuecentric.com>]
Sent: Monday, February 20, 2012 9:06 AM
To: Michael Dorsey
Cc: Rachelle Galant; Peter Shubiak
Subject: RE: Actavis 852 / 867 data

Hello Michael,

I havent received any updates from Auburn, Quest or Master RX but I will follow-up with them again.

Are you still expecting data from Master RX as I dont see this on your list below. I will get back to Jon Taylor at Top RX and answer the questions he has and hopefully this will get the data flowing soon. The timing of when this will be complete will depend a lot on the Trading Partners as to when they are ready to start sending data and when they respond as to what ZA codes and definitions they will be sending so we can create an 852 map, and how they will be sending the data (AS2 or Van). I received a response from Quest in January from Debbie Boaz stating Actavis had advised her that you wanted this data by March but I havent heard from her since. Quest is only sending 867 data so it does not require any mapping so hopefully this will not take too long once they start sending data. It will depend on when they are ready to send it. I will follow-up with these TPs and update you once I receive responses. Please confirm whether or not we should proceed with Master RX data also.

Thank you.

Kathi Williams

Customer Support Analyst

ValueCentric, LLC

Phone: (716) 972-1631

Support Phone: (716) 972-1660

Support E-mail: Support@valuecentric.com <<mailto:Support@valuecentric.com>>

From: Michael Dorsey [<mailto:MDORSEY@actavis.com> <<mailto:MDORSEY@actavis.com>>]

Sent: Friday, February 17, 2012 6:29 PM

To: kathi.williams@valuecentric.com <<mailto:kathi.williams@valuecentric.com>>; Peter Shubiak

Subject: Re: Actavis 852 / 867 data

,

Thank you for the update. We have given TopRx, Auburn and Quest a March 15th target date for completion. With that said, what is the probability of this from your stand point?

Thank you,

Mike Dorsey

Director, National Accounts

262.377.0874 (O)

262.421.4636 (F)

908.906.9838 (C)

***** Confidentiality Notice: *****

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited.

If you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox.

***** Confidentiality Notice: *****

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited.

If you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox.

***** Confidentiality Notice: *****

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited.

If you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper del

0KB / Blank File